In silico designing of novel inhibitors for triple inhibition of Aldose Reductase, Aldose Reductase like protein 1, and Aldehyde Reductase.
Cancer is a well-known and well-studied disease. There are environmental as well as genetic factors that trigger cancer. All forms of cancer are associated with deregulation of genes and proteins. Aldose reductase, Aldose Reductase like protein 1 and Aldehyde Reductase are homologous proteins which are overexpressed in different types of cancer. They are NADPH-dependent oxidoreductases. The active site is conserved, thus there is very less substrate specificity among those proteins. In this study, novel molecules targeting the three proteins are designed. Molecular docking is performed to study the binding affinity of each ligand towards the targets. The six molecules studied are found to have better in silico affinity than tolrestat (known inhibitor) The designed molecules are predicted to be orally active. Finally, Molecular Dynamics Simulation shows that the protein ligand complexes are stable in aqueous environment.